Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Common Equity (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Common Equity for 15 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity rose 3.45% to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.1 million, a 3.45% increase, with the full-year FY2024 number at -$129000.0, down 103.89% from a year prior.
  • Common Equity was $1.1 million for Q3 2025 at NovaBay Pharmaceuticals, down from $4.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $17.7 million in Q1 2022 to a low of -$158.2 million in Q4 2022.
  • A 5-year average of -$1.5 million and a median of $7.0 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: crashed 1654.93% in 2022, then soared 3754.38% in 2025.
  • NovaBay Pharmaceuticals' Common Equity stood at $10.2 million in 2021, then plummeted by 1654.93% to -$158.2 million in 2022, then skyrocketed by 102.1% to $3.3 million in 2023, then tumbled by 103.89% to -$129000.0 in 2024, then skyrocketed by 959.69% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Common Equity are $1.1 million (Q3 2025), $4.2 million (Q2 2025), and $6.2 million (Q1 2025).